Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 5.05% is 988% above its 5-year average of 0.46%, near the high end of its 5-year range (-21.60%–8.62%).
7.16% above its 12-month average of 4.71%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 7.24%.
NET PROFIT MARGIN
5.05%
NET PROFIT MARGIN AVG TTM
4.71%
NET PROFIT MARGIN AVG 3Y
1.68%
NET PROFIT MARGIN AVG 5Y
0.46%
NET PROFIT MARGIN AVG 10Y
0.25%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+7.16%
CURRENT VS 3Y AVG
+200.11%
CURRENT VS 5Y AVG
+987.53%
CURRENT VS 10Y AVG
+1932.54%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 461 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Amneal Pharmaceuticals, Inc.
Market Cap
$6.50B
Net Profit Margin
5.05%
TTM Avg
4.71%
3Y Avg
1.68%
5Y Avg
0.46%
Market Cap
$6.61B
Net Profit Margin
-236.95%
TTM Avg
-945.70%
3Y Avg
-3296.24%
5Y Avg
-3620.73%
Market Cap
$6.62B
Net Profit Margin
-5.51%
TTM Avg
7.00%
3Y Avg
-0.29%
5Y Avg
-8.82%
Market Cap
$6.32B
Net Profit Margin
-89.09%
TTM Avg
-187.61%
3Y Avg
-9430.16%
5Y Avg
-6286.77%
Market Cap
$6.68B
Net Profit Margin
10.60%
TTM Avg
11.45%
3Y Avg
11.66%
5Y Avg
12.42%
Market Cap
$6.86B
Net Profit Margin
-7585.86%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.06B
Net Profit Margin
-3602.68%
TTM Avg
-5857.26%
3Y Avg
-13524.50%
5Y Avg
-10844.39%
Market Cap
$7.23B
Net Profit Margin
-64.64%
TTM Avg
-52.37%
3Y Avg
-49.29%
5Y Avg
-43.60%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.50B | 5.05% | 4.71% | 1.68% | 0.46% |
| GRAIL Inc. (GRAL)vs › | $6.61B | -236.95% | -945.70% | -3296.24% | -3620.73% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.62B | -5.51% | 7.00% | -0.29% | -8.82% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $6.32B | -89.09% | -187.61% | -9430.16% | -6286.77% |
| Chemed Corporation (CHE)vs › | $6.68B | 10.60% | 11.45% | 11.66% | 12.42% |
| Immunovant, Inc. (IMVT)vs › | $6.86B | -7585.86% | 0.00% | 0.00% | 0.00% |
| CG Oncology Inc. (CGON)vs › | $6.06B | -3602.68% | -5857.26% | -13524.50% | -10844.39% |
| Alkermes plc (ALKS)vs › | $7.17B | 3.97% | 19.97% | 11.77% | 5.39% |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.23B | -64.64% | -52.37% | -49.29% | -43.60% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.53B | -3368.72% | -8808.10% | -41695.11% | -35876.65% |
Operating Margin
12.9%
Net Profit Margin
5.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 7.24% |
| 2026-03-31 | 8.62% |
| 2025-12-31 | 4.31% |
| 2025-09-30 | 0.30% |
| 2025-06-30 | 3.09% |
| 2025-03-31 | 1.75% |
| 2024-12-31 | -4.25% |
| 2024-09-30 | -0.02% |
| 2024-06-30 | 0.85% |
| 2024-03-31 | -13.90% |
| 2023-12-31 | -15.99% |
| 2023-09-30 | 1.56% |
| 2023-06-30 | 1.99% |
| 2023-03-31 | -1.25% |
| 2022-12-31 | -0.71% |
| 2022-09-30 | -0.49% |
| 2022-06-30 | -21.60% |
| 2022-03-31 | -0.43% |
| 2021-12-31 | -1.19% |
| 2021-09-30 | -0.80% |
| 2021-06-30 | 2.72% |
| 2021-03-31 | 1.36% |
| 2020-12-31 | -0.60% |
| 2020-09-30 | -1.73% |
| 2020-06-30 | -2.58% |
| 2020-03-31 | 23.08% |
| 2019-12-31 | -8.09% |
| 2019-09-30 | -70.05% |
| 2019-06-30 | -4.18% |
| 2019-03-31 | -10.73% |
| 2018-12-31 | -1.76% |
| 2018-09-30 | 1.46% |
| 2018-06-30 | -53.03% |
| 2018-03-31 | 18.73% |
| 2017-12-31 | 20.99% |
| 2017-09-30 | 10.51% |
| 2017-06-30 | 14.41% |
| 2017-03-31 | 18.73% |
| 2016-12-31 | 18.05% |
